Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS).
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience
Bonavita, Simona;Signoriello, Elisabetta;Gallo, Antonio;Abbadessa, Gianmarco;
2020
Abstract
Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.